A phase II, randomised, double blind, placebo controlled, three way crossover study to assess the bronchodilator effect of RPL554 administered in addition to open label tiotropium in patients with COPD.

Trial Profile

A phase II, randomised, double blind, placebo controlled, three way crossover study to assess the bronchodilator effect of RPL554 administered in addition to open label tiotropium in patients with COPD.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs RPL 554 (Primary) ; Tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Verona Pharma
  • Most Recent Events

    • 09 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 07 Sep 2017 Results presented in an Arix Bioscience media release.
    • 07 Sep 2017 Primary endpoint (Average FEV1 on the third day of dosing) has been met according to Verona Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top